$1.48
4.23%
Nasdaq, Oct 23, 11:32 am EDT. Market open.
ISIN
US74584P1030
Symbol
PULM

Pulmatrix Inc Stock price

$1.42
-0.28 16.47% 1M
+0.02 1.43% 6M
-0.81 36.32% YTD
-3.49 71.05% 1Y
-0.42 22.83% 3Y
-12.58 89.86% 5Y
-278.58 99.49% 10Y
-3,623.58 99.96% 20Y
Nasdaq, Closing price Thu, Oct 22 2026
-0.15 9.55%
ISIN
US74584P1030
Symbol
PULM
Industry

Is Pulmatrix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,102 stocks worldwide.

Key metrics

Basic
Market capitalization
$5.2m
Enterprise Value
$3.0m
Net debt
positive
Cash
$2.2m
Shares outstanding
3.7m
Valuation
P/E
-
P/S | estimate
- | 0.3
EV/Sales | estimate
- | 0.2
EV/FCF | ex SBC
negative | negative
P/B
2.0
Financial Health
Equity Ratio
92.1%
Return on Equity
-135.5%
ROCE
-
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$20.0k | -
SBC as % of FCF
-
SBC Growth 1Y
-90.9%
Share Count Growth 1Y
0.0%
Shareholder Yield
0.0%
Financials
Revenue | estimate
- | $16.8m
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow | ex SBC
$-3.9m | $-3.9m
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
51.3%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
-
FCF per Share
$-1.1
Short interest
1.4%
Employees
2
Rev per Employee
$0.0

Pulmatrix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Pulmatrix Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Pulmatrix Inc forecast:

Buy
86%
Hold
14%

Pulmatrix Inc Events

Upcoming Event
NOV
5
Q3 2026 Earnings Call
in 13 days

Financial data from Pulmatrix Inc

Dec '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.13 5.13
34% 34%
-
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.17 -5.17
28% 28%
-
Net Profit -5.16 -5.16
46% 46%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pulmatrix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pulmatrix Inc Stock News

Neutral
GlobeNewsWire
●
one day ago
In naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142) “Speedy,” a PTC-2105-treated mouse now more than 167 weeks old, has outlived every saline-treated negative control in his study by more than 20% and remains active day and night New “Team Speedy” webpag...
Neutral
GlobeNewsWire
●
about one month ago
Founder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicine Eos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward first-in-human studies for sarcopenia and sarcopenic obesity Eos anticipates closing of Pulmatrix, Inc. merger in Q4 subject to customary closing conditions HOUSTON, Sept.
Neutral
PRNewsWire
●
2 months ago
Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX FRAMINGHAM, Mass., Aug. 13, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using it...
More Pulmatrix Inc News

Company Profile

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.

Head office United States
CEO Mr. Ludlum
Employees 2
Founded 2015
Website www.pulmatrix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today